SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tanimoto Sarina
(Last) (First) (Middle)
C/O ARS PHARMACEUTICALS, INC.
11682 EL CAMINO REAL, SUITE 120
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARS Pharmaceuticals, Inc. [ SPRY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
X Officer (give title below) Other (specify below)
CHIEF MEDICAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
02/26/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 3,276,854 D
Common Stock 02/26/2024 S 100(1) D $9.01 1,772,750 I By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020(2)
Common Stock 02/26/2024 S 500(1) D $9.01 2,099,500 I By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006(3)
Common Stock 02/26/2024 S 100(1) D $9.01 1,772,750 I By Sarina Tanimoto Charitable Remainder Unitrust Dated January 7, 2020(4)
Common Stock 02/28/2024 S 25,456(1) D $9.0205(5) 1,747,294 I By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020(2)
Common Stock 02/28/2024 S 49,019(1) D $9.0212(6) 2,050,481 I By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006(3)
Common Stock 02/28/2024 S 24,303(1) D $9.0205(7) 1,748,447 I By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020(4)
Common Stock 4,126,822 I By Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.
2. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
3. The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.
4. The Reporting Person is trustee of the trust.
5. The weighted average sale price for the transaction reported was $9.0205, and the range of prices were between $9.00 and $9.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
6. The weighted average sale price for the transaction reported was $9.0212, and the range of prices were between $9.00 and $9.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
7. The weighted average sale price for the transaction reported was $9.0205, and the range of prices were between $9.00 and $9.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Kathleen Scott, Attorney-in-Fact 02/28/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
ARS Pharmaceuticals (NASDAQ:SPRY)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more ARS Pharmaceuticals Charts.
ARS Pharmaceuticals (NASDAQ:SPRY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more ARS Pharmaceuticals Charts.